Menarini
The Menarini Group is an Italian pharmaceutical company. Its headquarters is in Florence, Tuscany, and it has three divisions: Menarini Ricerche, Menarini Biotech, and Menarini Diagnostics. It develops pharmacological solutions for cardiovascular diseases, oncology, pain/inflammation, asthma and anti-infectives. Menarini's research activities are carried out through Menarini Ricerche, which deals with all R&D activities, from the creation of new projects up to the drug registration. Its Menarini Biotech follows the creation of a biotechnological drug from the very early stages of research, through to the pilot scale and up to industrial production. The Group's Menarini Diagnostics division is a health care company with a worldwide network of affiliates partners and distributors focused on diabetes, haematology, clinical chemistry, urinalysis, and immunology. In 2020, the company had 17,650 employees worldwide.
Download report
Favorite
Financial
Marketed Drugs
Clinical Trials
Financial
Stock price
No data
Company Revenue
No data
Revenue by Drug
Marketed Drugs
Therapeutic Areas:
All
Classification:
All
Include Generics:
Trade Name | Drug Name | Approved | Patent Expires | Indication |
|---|---|---|---|---|
| Adenuric | Febuxostat | 2008-04-21 | 2024-2031 | |
| Ciambra | Pemetrexed | 2015-12-02 | 2035 | |
| Quofenix | Delafloxacin | 2019-12-16 | 2025-2033 | |
| Ranexa (previously latixa) | Ranolazine | 2008-07-08 | 2038 | |
| Spedra | Avanafil | 2013-06-21 | 2025 | |
| Tenkasi (previously orbactiv) | Oritavancin | 2015-03-19 | 2029-2035 | |
| Vaborem | Meropenem, Vaborbactam | 2018-11-20 | 2031-2039 | |
| Ranexa | Ranolazine | 2006-01-27 | 2038 |
Clinical Trials
Therapeutic Areas:
All
Classification:
All
Approval:
All
Status:
All
Phases:
All
Drug Name | Phase 1 | Phase 2 | Phase 3 | Phase 4 | Indication |
|---|---|---|---|---|---|
1
2
>
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use